Windtree Therapeutics, Inc.
WINT
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -0.99% | 5.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.59% | 4.31% | |||
| Operating Income | 2.59% | -4.31% | |||
| Income Before Tax | -162.82% | -250.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -162.82% | -246.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -162.82% | -246.19% | |||
| EBIT | 2.59% | -4.31% | |||
| EBITDA | 2.60% | -4.44% | |||
| EPS Basic | 33.98% | -1,270.17% | |||
| Normalized Basic EPS | 40.61% | -114.22% | |||
| EPS Diluted | 33.98% | -1,270.17% | |||
| Normalized Diluted EPS | 40.61% | -114.22% | |||
| Average Basic Shares Outstanding | 348.03% | 533.64% | |||
| Average Diluted Shares Outstanding | 348.03% | 533.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | 1.00% | -1.20% | |||